0000914475-24-000009.txt : 20240110 0000914475-24-000009.hdr.sgml : 20240110 20240110163124 ACCESSION NUMBER: 0000914475-24-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240108 FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORMAN KEVIN CHARLES CENTRAL INDEX KEY: 0001201096 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24526940 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1704922274.xml FORM 4 X0508 4 2024-01-08 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001201096 GORMAN KEVIN CHARLES 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer 1 Common Stock 2024-01-08 4 M 0 105835 19.59 A 605589 D Common Stock 2024-01-08 4 S 0 105835 132.4375 D 499754 D Common Stock 2024-01-09 4 M 0 62023 19.59 A 561777 D Common Stock 2024-01-09 4 S 0 62023 134.0131 D 499754 D Non-Qualified Stock Option 19.59 2024-01-08 4 M 0 105835 19.59 D 2024-01-16 Common Stock 105835 62023 D Non-Qualified Stock Option 19.59 2024-01-09 4 M 0 62023 19.59 D 2024-01-16 Common Stock 62023 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024. /s/ Darin Lippoldt, Attorney-in-Fact 2024-01-10